{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:49Z","timestamp":1786982209681,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049559"],"award-info":[{"award-number":["RS-2020-NR049559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049559"],"award-info":[{"award-number":["RS-2020-NR049559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049559"],"award-info":[{"award-number":["RS-2020-NR049559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049559"],"award-info":[{"award-number":["RS-2020-NR049559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049559"],"award-info":[{"award-number":["RS-2020-NR049559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03108-2","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T03:57:56Z","timestamp":1763438276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination of SH003 and paclitaxel modulates tumor microenvironment and inhibits metastasis of metastatic melanoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Sang-Eun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Beom","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhoo","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Gyu","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"11","key":"3108_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366\u201379. https:\/\/doi.org\/10.1080\/15384047.2019.1640032.","journal-title":"Cancer Biol Ther"},{"key":"3108_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1471037","volume":"16","author":"X Cui","year":"2025","unstructured":"Cui X, Song J, Li Q, Ren J. Identification of biomarkers and target drugs for melanoma: a topological and deep learning approach. Front Genet. 2025;16:1471037. https:\/\/doi.org\/10.3389\/fgene.2025.1471037.","journal-title":"Front Genet"},{"issue":"3","key":"3108_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000959","volume":"34","author":"G De Pinto","year":"2024","unstructured":"De Pinto G, Mignozzi S, La Vecchia C, Levi F, Negri E, Santucci C. Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma Res. 2024;34(3):265\u201375. https:\/\/doi.org\/10.1097\/CMR.0000000000000959.","journal-title":"Melanoma Res"},{"key":"3108_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1512942","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Liu X, Hu L, Li X, Xin H, Zhu S. Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045. Front Oncol. 2024;14:1512942. https:\/\/doi.org\/10.3389\/fonc.2024.1512942.","journal-title":"Front Oncol"},{"key":"3108_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00271","volume":"5","author":"PT Kuo","year":"2018","unstructured":"Kuo PT, Zeng Z, Salim N, Mattarollo S, Wells JW, Leggatt GR. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front Med. 2018;5:271. https:\/\/doi.org\/10.3389\/fmed.2018.00271.","journal-title":"Front Med"},{"issue":"3","key":"3108_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6606056","volume":"104","author":"S Amatschek","year":"2011","unstructured":"Amatschek S, Lucas R, Eger A, Pflueger M, Hundsberger H, Knoll C, et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer. 2011;104(3):469\u201379. https:\/\/doi.org\/10.1038\/sj.bjc.6606056.","journal-title":"Br J Cancer"},{"issue":"1","key":"3108_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/19768354.2024.2402024","volume":"28","author":"B Kim","year":"2024","unstructured":"Kim B, Park YY, Lee JH. CXCL10 promotes melanoma angiogenesis and tumor growth. Anim Cells Syst. 2024;28(1):453\u201365. https:\/\/doi.org\/10.1080\/19768354.2024.2402024.","journal-title":"Anim Cells Syst"},{"key":"3108_CR8","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.ejca.2024.115121","volume":"214","author":"JP Pham","year":"2025","unstructured":"Pham JP, Staeger R, Joshua AM, Liu J, da Silva IP, Dummer R, et al. An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma. Eur J Cancer. 2025;214:115121. https:\/\/doi.org\/10.1016\/j.ejca.2024.115121.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3108_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17512433.2024.2431513","volume":"17","author":"J Justice","year":"2024","unstructured":"Justice J, Kankaria RA, Johnson DB. Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity. Expert Rev Clin Pharmacol. 2024;17(12):1115\u201325. https:\/\/doi.org\/10.1080\/17512433.2024.2431513.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"26","key":"3108_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"issue":"7","key":"3108_CR11","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.clinthera.2012.06.009","volume":"34","author":"MC Ravnan","year":"2012","unstructured":"Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012;34(7):1474\u201386. https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.009.","journal-title":"Clin Ther"},{"issue":"9","key":"3108_CR12","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","volume":"15","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15(9):e371\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(14)70072-5.","journal-title":"Lancet Oncol"},{"key":"3108_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992. https:\/\/doi.org\/10.3389\/fimmu.2022.954992.","journal-title":"Front Immunol"},{"issue":"3","key":"3108_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"3108_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory t cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. https:\/\/doi.org\/10.1186\/s12943-020-01234-1.","journal-title":"Mol Cancer"},{"issue":"2","key":"3108_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/mmt-2017-0003","volume":"4","author":"A Gupta","year":"2017","unstructured":"Gupta A, Gomes F, Lorigan P. The role for chemotherapy in the modern management of melanoma. Melanoma Manag. 2017;4(2):125\u201336. https:\/\/doi.org\/10.2217\/mmt-2017-0003.","journal-title":"Melanoma Manag"},{"issue":"1","key":"3108_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12961-9","volume":"24","author":"FR Di Pietro","year":"2024","unstructured":"Di Pietro FR, Marinelli D, Verkhovskaia S, Poti G, Falcone R, Carbone ML, et al. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience. BMC Cancer. 2024;24(1):1220. https:\/\/doi.org\/10.1186\/s12885-024-12961-9.","journal-title":"BMC Cancer"},{"issue":"1","key":"3108_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","volume":"42","author":"S Mielke","year":"2006","unstructured":"Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2005.06.030.","journal-title":"Eur J Cancer"},{"issue":"5","key":"3108_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","volume":"6","author":"TJ Postma","year":"1995","unstructured":"Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6(5):489\u201394. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a059220.","journal-title":"Ann Oncol"},{"key":"3108_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/492173","volume":"2014","author":"YK Choi","year":"2014","unstructured":"Choi YK, Cho SG, Woo SM, Yun YJ, Park S, Shin YC. Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm. 2014;2014:492173. https:\/\/doi.org\/10.1155\/2014\/492173.","journal-title":"Mediators Inflamm"},{"issue":"1\u20132","key":"3108_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-016-2875-y","volume":"426","author":"HS Choi","year":"2017","unstructured":"Choi HS, Cho SG, Kim MK, Lee HJ, Moon SH, Jang HJ. Sh003 enhances paclitaxel chemosensitivity in MCF-7\/PAX breast cancer cells through inhibition of MDR1 activity. Mol Cell Biochem. 2017;426(1\u20132):1\u20138. https:\/\/doi.org\/10.1007\/s11010-016-2875-y.","journal-title":"Mol Cell Biochem"},{"key":"3108_CR22","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20170125","author":"HS Seo","year":"2017","unstructured":"Seo HS, Ku JM, Lee HJ, Woo JK, Cheon C, Kim M, et al. SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells. Biosci Rep. 2017. https:\/\/doi.org\/10.1042\/BSR20170125.","journal-title":"Biosci Rep"},{"issue":"1","key":"3108_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-016-1490-5","volume":"16","author":"YJ Choi","year":"2016","unstructured":"Choi YJ, Choi YK, Lee KM, Cho SG, Kang SY, Ko SG. SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med. 2016;16(1):507. https:\/\/doi.org\/10.1186\/s12906-016-1490-5.","journal-title":"BMC Complement Altern Med"},{"issue":"8","key":"3108_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02924-w","volume":"11","author":"TW Kim","year":"2020","unstructured":"Kim TW, Cheon C, Ko SG. SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells. Cell Death Dis. 2020;11(8):717. https:\/\/doi.org\/10.1038\/s41419-020-02924-w.","journal-title":"Cell Death Dis"},{"key":"3108_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4120334","volume":"2021","author":"K Lee","year":"2021","unstructured":"Lee K, Ku JM, Choi YJ, Hwang HH, Jeong M, Kim YG, et al. Herbal prescription SH003 alleviates Docetaxel-induced neuropathic pain in C57BL\/6 mice. Evid Based Complement Alternat Med. 2021;2021:4120334. https:\/\/doi.org\/10.1155\/2021\/4120334.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"3108_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0565-5","volume":"7","author":"SK Wculek","year":"2019","unstructured":"Wculek SK, Amores-Iniesta J, Conde-Garrosa R, Khouili SC, Melero I, Sancho D. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. J Immunother Cancer. 2019;7(1):100. https:\/\/doi.org\/10.1186\/s40425-019-0565-5.","journal-title":"J Immunother Cancer"},{"key":"3108_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/15347354241293451","volume":"23","author":"C Cheon","year":"2024","unstructured":"Cheon C, Lee HW, Sym SJ, Ko SG. Safety of the herbal medicine SH003 in patients with solid cancer: a multi-center, single-arm, open-label, dose-escalation phase I study. Integr Cancer Ther. 2024;23:15347354241293451. https:\/\/doi.org\/10.1177\/15347354241293451.","journal-title":"Integr Cancer Ther"},{"issue":"7","key":"3108_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04064-6","volume":"74","author":"YJ Choi","year":"2025","unstructured":"Choi YJ, Lee SE, Kim D, Lim HI, Choi DK, Park BK, et al. The combination of SH003 and DTX induces cytotoxic cell infiltration in anti-PD1 resistant lung cancer. Cancer Immunol Immunother. 2025;74(7):198. https:\/\/doi.org\/10.1007\/s00262-025-04064-6.","journal-title":"Cancer Immunol Immunother"},{"key":"3108_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121874","author":"C Li","year":"2022","unstructured":"Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of melanoma. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12121874.","journal-title":"Biomolecules"},{"issue":"6","key":"3108_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/labinvest.2017.9","volume":"97","author":"A Kawakami","year":"2017","unstructured":"Kawakami A, Fisher DE. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest. 2017;97(6):649\u201356. https:\/\/doi.org\/10.1038\/labinvest.2017.9.","journal-title":"Lab Invest"},{"key":"3108_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084243","author":"J Tian","year":"2024","unstructured":"Tian J, Quek C. Understanding the tumor microenvironment in melanoma patients with in-transit metastases and its impacts on immune checkpoint immunotherapy responses. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084243.","journal-title":"Int J Mol Sci"},{"key":"3108_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102870","author":"I Falcone","year":"2020","unstructured":"Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, et al. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12102870.","journal-title":"Cancers (Basel)"},{"key":"3108_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1157306","volume":"14","author":"M Sousa-Pimenta","year":"2023","unstructured":"Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306. https:\/\/doi.org\/10.3389\/fphar.2023.1157306.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3108_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phyplu.2021.100111","volume":"1","author":"JM Ku","year":"2021","unstructured":"Ku JM, Hong SH, Kim HI, Kim MJ, Ku S-J, Bae K-R, et al. SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7\/ADR cells. Phytomedicine Plus. 2021;1(4):100111. https:\/\/doi.org\/10.1016\/j.phyplu.2021.100111.","journal-title":"Phytomedicine Plus"},{"issue":"4","key":"3108_CR35","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3892\/mmr.2016.5722","volume":"14","author":"EK Choi","year":"2016","unstructured":"Choi EK, Kim SM, Hong SW, Moon JH, Shin JS, Kim JH, et al. SH003 selectively induces p73\u2013dependent apoptosis in triple\u2013negative breast cancer cells. Mol Med Rep. 2016;14(4):3955\u201360. https:\/\/doi.org\/10.3892\/mmr.2016.5722.","journal-title":"Mol Med Rep"},{"key":"3108_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114893","volume":"285","author":"NR Han","year":"2022","unstructured":"Han NR, Kim KC, Kim JS, Ko SG, Park HJ, Moon PD. The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes kirilowii (Maxim.) or its active constituent Nodakenin. J Ethnopharmacol. 2022;285:114893. https:\/\/doi.org\/10.1016\/j.jep.2021.114893.","journal-title":"J Ethnopharmacol"},{"issue":"10","key":"3108_CR37","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res. 2023;29(10):1835\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1922.","journal-title":"Clin Cancer Res"},{"key":"3108_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:2105. https:\/\/doi.org\/10.3389\/fimmu.2020.02105.","journal-title":"Front Immunol"},{"key":"3108_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103773","volume":"177","author":"D Presti","year":"2022","unstructured":"Presti D, Dall\u2019Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. Crit Rev Oncol Hematol. 2022;177:103773. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103773.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3108_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1381251","volume":"14","author":"L Long","year":"2024","unstructured":"Long L, Fei X, Chen L, Yao L, Lei X. Potential therapeutic targets of the JAK2\/STAT3 signaling pathway in triple-negative breast cancer. Front Oncol. 2024;14:1381251. https:\/\/doi.org\/10.3389\/fonc.2024.1381251.","journal-title":"Front Oncol"},{"key":"3108_CR41","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/JIR.S353489","volume":"15","author":"T Mengie Ayele","year":"2022","unstructured":"Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, Bogale Kassie A, Chekol Abebe E. Role of JAK2\/STAT3 signaling pathway in the Tumorigenesis, chemotherapy Resistance, and treatment of solid tumors: A systemic review. J Inflamm Res. 2022;15:1349\u201364. https:\/\/doi.org\/10.2147\/JIR.S353489.","journal-title":"J Inflamm Res"},{"key":"3108_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177. https:\/\/doi.org\/10.3389\/fonc.2022.1023177.","journal-title":"Front Oncol"},{"key":"3108_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128.","journal-title":"Front Oncol"},{"issue":"1","key":"3108_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03108-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:49:43Z","timestamp":1769485783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03108-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03108-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The animal experiments were performed following protocols approved by the Institutional Animal Care and Use Committees of Kyung Hee University (KHSASP-23-485).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"2"}}